Oral delivery of peptides/proteins

24 november 2010 INVITATION TO BID FOR PATENT RIGHTS Please be advised that Jederstrom Pharmaceuticals AB intends to offer for sale its patent portfolio that relates to oral delivery of therapeutic peptides/proteins. Various pharma companies including big pharma companies have recently expressed an interest in acquiring Jederstrom Pharmaceuticals' complexing method for enabling oral delivery of therapeutic peptides. The complex Oral administration of peptides: The complexing method with hyaluronic acid allows for removal of the interstitial space in peptides. This means that the peptide in the complex (hyaluronic acid + peptide) is more than 10 times smaller than the original peptide. This change in size allows for oral uptake of complexes of therapeutic peptides such as for instance insulin. Animal studies support said concept, but more work needs to be done before diabetic patients can reliably take a tablet instead of an injection. Traditional administration of peptides: In addition to opportunities such as the abovementioned orally administrated insulin concept, Jederstrom Pharmaceuticals believes that the complex technology offers a far more interesting business opportunity for big pharma as the complexing method may be used with a variety of therapeutic peptides and potentially, every new complex that is made with an existing peptide using this method could be patentable. The complexed peptide has the potential to serve as a prodrug with long term stability (counting in years). When it gets into contact with serum it splits into the original peptide and hyaluronic acid. The complex should therefore have a relatively high probability of making it through the development phases to a finished product since the side effects of hyaluronic acid and the peptide in question will already be known Complexed insulin as an example: Subcutaneous injections of complexed insulin have a very quick onset. The biological activity starts within 15 min. The glucose decrements do not differ from native insulin indicating a complete split of the complex in contact with serum. The receptor can only be activated by an intact insulin molecule. The dose of complexed insulin may affect the length of the activity (the duration) but not the size of the decrements. Oral administration of complexed insulin tended to have a longer time for onset of the glucose decrements. Please note that we should receive your indicative bid before 21 January 2011. For further information MAILTO: info@jederstrom.com BUSINESS REPLY MAIL: Jederstrom Pharmaceuticals AB Box 23218 SE-104 35 Stockholm www.jederstrom.com Gustaf Jederström Peter Werme Chairman of the Board Director Phone: +46 8 6897015 +46 706267899 Mobile: +46 705176237 peter.werme@jederstrom.com Fax: +46 8 6897025 E-mail:gustaf.jederstrom@jederstrom.com Jederstrom Pharmaceuticals , www.jederstrom.com, (Table of Patents and pending applications encl.) [HUG#1464504] Press release PDF: http://hugin.info/144857/R/1464504/402921.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Jederstrom Pharmaceuticals AB via Thomson Reuters ONE